X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (593) 593
Patent (143) 143
Magazine Article (15) 15
Publication (15) 15
Conference Proceeding (12) 12
Book Chapter (5) 5
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (173) 173
index medicus (159) 159
oncology (130) 130
male (112) 112
female (109) 109
middle aged (97) 97
aged (95) 95
physics (86) 86
adult (82) 82
cancer (79) 79
chemotherapy (58) 58
lung neoplasms - drug therapy (57) 57
cryptography (55) 55
advertising (54) 54
display (54) 54
education (54) 54
seals (54) 54
arrangements or circuits for control of indicating devicesusing static means to present variable information (53) 53
aged, 80 and over (51) 51
respiratory system (49) 49
chemistry (48) 48
mutation (48) 48
biochemistry & molecular biology (45) 45
carcinoma, non-small-cell lung - drug therapy (43) 43
lung cancer, non-small cell (43) 43
human necessities (42) 42
lung neoplasms - pathology (41) 41
lung neoplasms - genetics (40) 40
treatment outcome (40) 40
prognosis (39) 39
gefitinib (38) 38
non-small cell lung cancer (36) 36
optics (36) 36
analysis (35) 35
animals (35) 35
care and treatment (35) 35
metallurgy (34) 34
neoplasm staging (34) 34
hygiene (33) 33
medical or veterinary science (33) 33
polymer science (33) 33
carcinoma, non-small-cell lung - genetics (32) 32
antineoplastic agents - therapeutic use (31) 31
adenocarcinoma (30) 30
apoptosis (30) 30
carcinoma, non-small-cell lung - pathology (30) 30
disease-free survival (30) 30
lung cancer (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (29) 29
devices or arrangements, the optical operation of which ismodified by changing the optical properties of the medium of thedevices or arrangements for the control of the intensity,colour, phase, polarisation or direction of light, e.g.switching, gating, modulating or demodulating (29) 29
frequency-changing (29) 29
identification (29) 29
non-linear optics (29) 29
optical analogue/digital converters (29) 29
optical logic elements (29) 29
techniques or procedures for the operation thereof (29) 29
electricity (28) 28
hematology, oncology and palliative medicine (27) 27
microbiology (27) 27
tyrosine (27) 27
carcinoma (25) 25
lung neoplasms - mortality (25) 25
survival (25) 25
tumors (25) 25
cell biology (24) 24
protein kinase inhibitors - therapeutic use (24) 24
proteins (24) 24
research (24) 24
surgery (24) 24
epidermal growth factor (23) 23
expression (23) 23
preparations for medical, dental, or toilet purposes (23) 23
biochemistry (22) 22
medical colleges (22) 22
pulmonary/respiratory (22) 22
receptor, epidermal growth factor - genetics (22) 22
original (21) 21
생물학 (21) 21
cisplatin (20) 20
erlotinib (20) 20
medicine, general & internal (20) 20
original article (20) 20
retrospective studies (20) 20
survival rate (20) 20
activation (19) 19
metastasis (19) 19
mice (19) 19
open-label (19) 19
mutations (18) 18
acquired-resistance (17) 17
biotechnology & applied microbiology (17) 17
cell line, tumor (17) 17
enzymology (17) 17
gene (17) 17
kinases (17) 17
beer (16) 16
cell lung-cancer (16) 16
clinical trials (16) 16
docetaxel (16) 16
gene expression (16) 16
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S125 - S125
Journal Article
Lung Cancer, ISSN 0169-5002, 2016, Volume 93, pp. 59 - 68
Highlights • 3rd generation EGFR TKIs are T790M selective with minimal inhibition in WT EGFR. • The 3rd generation EGFR TKIs are highly active and are well... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Osimertinib | Rociletinib | HM61713 | Tyrosine kinase inhibitor | Epidermal growth factor receptor mutations | Non-small cell lung cancer | GEFITINIB | ADENOCARCINOMA | ACQUIRED-RESISTANCE | EGFR MUTATIONS | COMBINATION | CHEMOTHERAPY | HETEROGENEITY | CIRCULATING TUMOR DNA | ONCOLOGY | RESPIRATORY SYSTEM | AZD9291 | VEMURAFENIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Molecular Targeted Therapy | Antineoplastic Agents - pharmacology | Drug Evaluation, Preclinical | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Treatment Outcome | Clinical Trials as Topic | Blood-Brain Barrier - drug effects | Carcinoma, Non-Small-Cell Lung - mortality | Drug Discovery | Blood-Brain Barrier - metabolism | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Tyrosine | Lung cancer, Non-small cell | Epidermal growth factor | Chemotherapy | Phenols | Lung cancer, Small cell | Development and progression | Metastasis | Cancer
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 2104 - 2104
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2018, Volume 378, Issue 2, pp. 113 - 125
In 556 patients with previously untreated lung cancer bearing EGFR mutations, osimertinib and the first-generation EGFR inhibitors erlotinib and gefitinib had... 
1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | CNS RESPONSE | AZD9291 | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Gefitinib | Lung Neoplasms - genetics | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Survival Rate | Piperazines - therapeutic use | Carcinoma, Non-Small-Cell Lung - mortality | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Aged | Erlotinib Hydrochloride - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Cancer patients | Care and treatment | Lung cancer, Non-small cell | Analysis | Tyrosine | Medical research | Epidermal growth factor receptors | Lung cancer | Clinical trials | Non-small cell lung carcinoma | Oncology | Metastasis | Gene deletion | Patients | Cancer therapies | Clinical outcomes | Chemotherapy | Epidermal growth factor | Clonal deletion | Protein-tyrosine kinase receptors | Protein-tyrosine kinase | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Cancer Research, ISSN 0008-5472, 08/2015, Volume 75, Issue 15 Supplement, pp. 741 - 741
Journal Article
Cancer Research, ISSN 0008-5472, 07/2017, Volume 77, Issue 13 Supplement, pp. 2054 - 2054
Journal Article
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 713 - 713
Journal Article
Lung Cancer, ISSN 0169-5002, 2016, Volume 97, pp. 73 - 80
Journal Article
International journal of radiation oncology, biology, physics, ISSN 0360-3016, 08/2019
The interest in combining radiotherapy (RT) with immunotherapy is increasing. We investigated the significance of lymphopenia in patients receiving... 
Journal Article
Lung Cancer, ISSN 0169-5002, 2017, Volume 108, pp. 29 - 37
Highlights • Cranial metastases are frequent sites of progression. • Surgery, stereotactic radiosurgery and/or WBRT has been the cornerstone of therapy. •... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | CNS metastases | BLOOM trial | Osimertinib | AZD3759 | Tyrosine kinase inhibitors | Non-small cell lung cancer | IMMUNE CHECKPOINT INHIBITORS | PHASE-III | WHOLE-BRAIN RADIOTHERAPY | OPEN-LABEL | DOSE WEEKLY ERLOTINIB | CELL LUNG-CANCER | NERVOUS-SYSTEM METASTASES | STEREOTACTIC RADIOSURGERY | ONCOLOGY | RESPIRATORY SYSTEM | LEPTOMENINGEAL CARCINOMATOSIS | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Antineoplastic Agents | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Treatment Outcome | Combined Modality Therapy | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Central Nervous System Neoplasms - secondary | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Central Nervous System Neoplasms - drug therapy | Medical colleges | Usage | Care and treatment | Metastasis | Lung cancer, Non-small cell | Radiosurgery | Tyrosine | Chemotherapy | Cancer
Journal Article
Journal of Lightwave Technology, ISSN 0733-8724, 9/2019, pp. 1 - 1
In this study, we report the successful demonstration of an intermediate-frequency-over-fiber (IFoF)-based radio access network (RAN) for 28 GHz... 
millimeter wave | 5G mobile communication | Bandwidth | Frequency conversion | Throughput | Downlink | distributed antenna system | Optical fiber communication | radio access network | radio-over-fiber | Antenna arrays | mobile fronthaul
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2019, Volume 37, Issue 15_suppl, pp. e14138 - e14138
Journal Article
Journal of Lightwave Technology, ISSN 0733-8724, 7/2019, pp. 1 - 1
We demonstrate 4×4 MIMO-supporting mmWave -based indoor 5G mobile network based on a distributed antenna system (DAS) that has over-the-air (OTA) interface to... 
Wireless communication | 5G communication system | millimeter wave | 5G mobile communication | Throughput | distributed antenna system | Optical network units | MIMO communication | radio-over-fiber
Journal Article
Journal Article